Article

Site-active steroid provides symptomatic relief for patients with dry eye disease

Miami—Anti-inflammatory treatment using loteprednol etabonate suspension 0.2% (Alrex, Bausch & Lomb) appears to offer a safe and useful option for symptomatic relief in patients with dry eye, according to Roberto Beraja, MD.

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Related Content
Researchers: New AI model reaches clinical-expert-level accuracy in complex medical scans
October 4th 2024

Researchers: New AI model reaches clinical-expert-level accuracy in complex medical scans

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

Aldeyra Therapeutics resubmits New Drug Application for reproxalap for the treatment of dry eye disease
October 3rd 2024

Aldeyra Therapeutics resubmits New Drug Application for reproxalap for the treatment of dry eye disease

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

NYU Langone receives $1.6 million grant from NIH to study Alzheimer, Parkinson progression
October 3rd 2024

NYU Langone receives $1.6 million grant from NIH to study Alzheimer, Parkinson progression

Novaliq and Laboratoires Théa announce partnership and European Commission approval of ciclosporin 0.1% eye drops solution
October 2nd 2024

Novaliq and Laboratoires Théa announce partnership and European Commission approval of ciclosporin 0.1% eye drops solution

© 2024 MJH Life Sciences

All rights reserved.